Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05968846 · ClinicalTrials.gov registry record · Phase 2
Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load
A Phase 2 study, sponsored by University of Tennessee Graduate School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT05968846: Completed Phase 2 study, sponsored by University of Tennessee Graduate School of Medicine.
NCT05968846 is a Phase 2 study that has completed, run by University of Tennessee Graduate School of Medicine. The registered enrollment target is 19 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05968846, a Phase 2 study, has completed, sponsored by University of Tennessee Graduate School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of organ-specific amyloid load.
Primary Outcome
The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of organ-specific amyloid load. The specific aim of this study is to measure visual and quantitative changes in organ-specific uptake of 124I-AT-01 from baseline, in patients with systemic amyloidosis, usin
Interventions
- DRUG Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2022-12-07 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 2 |
What the finished NCT05968846 record still lists
NCT05968846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01) is the first listed.
NCT05968846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05968846 about?
NCT05968846 is a clinical study titled "Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load". The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured by PET/CT imaging and further, whether these values correlate with changes in a subject's disease status and thereby enable monitoring of disease response over time in terms of org...
What is the current status of trial NCT05968846?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2022-12-07. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT05968846?
The interventions under investigation include: Injection of peptide p5+14 radiolabeled with iodine-124 (124I-AT-01) (DRUG).
Who is sponsoring clinical trial NCT05968846?
This trial is sponsored by University of Tennessee Graduate School of Medicine, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05968846's enrollment target sits among peer trials
19 1894th of 2000 higher than 103 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI